Rare lephants
Screener

Contineum Therapeutics, Inc.

CTNM ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Contineum Therapeutics, Inc.

Total Moat Score 5 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Proprietary brain-penetrant small molecule chemistry (PIPE-791, PIPE-307) and associated patents represent differentiated, validated intellectual property, evidenced by the J&J licensing deal.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 No manufacturing or scale cost advantage exists for a pre-revenue clinical-stage biotech.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 No commercial products exist; pricing power cannot be assessed until an asset reaches approval and payer negotiation.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effect applies to a clinical-stage drug development business.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 J&J has invested resources into PIPE-307/JNJ-89495120 development, creating modest switching cost, though the recent MS trial failure may reduce J&J's continued commitment.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 The CNS/inflammation/immunology small molecule space is crowded with well-funded competitors, offering no efficient-scale barrier specific to Contineum.